本帖最后由 老马 于 2012-1-13 21:20 编辑
: T* P \! Q# E8 e i0 _% ?
/ m, h3 r3 @# a6 S7 ]+ @爱必妥和阿瓦斯丁的比较
0 M3 R$ X' D- z1 O9 q% T
7 j" J' e z4 X" W
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/! }1 l9 r6 ^% O; `9 Q9 O
; N; r# X4 ~. s
$ R$ n% E7 S4 j! p+ w( P' a
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/( `" h, D" p! ]. o2 r4 `
==================================================! C; {% x4 N5 ^
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)' `# j9 \0 j! R( M b6 H
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
- z; X! k0 l6 |$ n6 k5 q* ~Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
9 T- @2 G H4 L9 B. x
|